Even though the establishment of CCR as indicative of the complete eradication of cells harboring the Ph chromosome is considered a significant milestone in the treatment of CML, the ultimate goal of therapy for CML remains getting patients rid of the molecular counterpart of the Ph chromosome, the BCR-ABL fusion gene transcript, as patients achieving CCR may still harbor up to 109 leukemic cells in their bodies [14]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.